What Adam May is saying
Physician & Biotech Investor
4 dated public stances tracked since 2026-03-23, most recently 2026-06-10. Each line carries the date and the venue it came from; quotation marks mean verbatim. Methodology.
The stances below are c8alpha's editorial distillation of Adam May's public commentary — television, podcasts, and interviews — compiled by automated transcript analysis and dated to the episode they came from. They may lag the speaker's current view and may contain extraction errors. Text in quotation marks is verbatim from the episode; everything else is our paraphrase. Adam May is not affiliated with c8alpha and has not endorsed this page. Nothing here is investment advice.
Think we got something wrong? Report a misattribution — we correct it or take it down.
Raw direction-aware returns on public statements — long calls credited when the price rose, shorts when it fell, shorts capped at −100% — in a rising market this mostly measures who was long, not who has skill. Returns run from the stance date; calls are rarely closed publicly, so fixed 90-day / 180-day / 1-year horizons are used. A horizon shows only once it has fully matured, and only at 5+ scored stances.
Most-argued themes
Tracked stances
bullish / bearish is a view they argued; owns / short is a position they said they hold.
2026-06-10
NKTR
bullish
Yet Another Value Podcast · video
Alopecia areata data showed deepening responses with longer treatment confirming a legitimate signal, the stock has sold off from the $92 secondary to the mid-50s on no fundamental change, and an unpriced Eli Lilly jury trial — where big pharma mishandled a…
“This stock is not trading as if they're going to get anything out of that lawsuit”
90d +32.9%
Adam May on $ABVX's blowout data and subsequent stock crash
2026-06-10
ABVX
bullish
Yet Another Value Podcast · video
Maintenance data blew out expectations — 40% clinical remission delta and double Rinvoq's endoscopic remission — while the cancer signal that crashed the stock collapses from 7 cases to 2 (one prostate, one breast) upon proper analysis: no genotoxic…
“I think the probability of downside is quite low because the worst case now the phase three data are in”
90d +21.3%
Adam May on $ABVX's blowout data and subsequent stock crash
2026-03-23
NKTR
owns
Yet Another Value Podcast · video
Rezpeg's eczema efficacy is materially understated due to Eli Lilly's botched data analysis and a single-patient visit anomaly at the primary endpoint week; OX40 competitor failures and safety signals (Kaposi's sarcoma) create a massive market vacuum, while…
“if I had to pick something that was the most asymmetric upside on my book, it would still be Nektar”
90d -11.6%
Adam May on investing in biotech $NKTR $ABVX
2026-03-23
ABVX
bullish
Yet Another Value Podcast · video
Abivax's obefazimod is the most obvious buyout candidate Adam has seen—post-phase-3 with unique unknown mechanism of action (no competitive overlap for any buyer), maintenance enrollment math publicly disclosed in their corporate deck implies a high remission…
“every successful ulcerative colitis trial in biotech has led to a buyout so far... this is after phase three”
90d -11.9%
Adam May on investing in biotech $NKTR $ABVX
Idea Scout Weekly
Every Sunday: who said what across the tape we track —
845 voices, 2,419 episodes and articles —
with side-flips and points of disagreement called out. Free.
How we track it.
Free · double opt-in · unsubscribe in one click
Newest stances reach Brief subscribers first; these pages update on a one-week lag.